Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of moxidectin, Synriam, and praziquantel in children with schistosomiasis
ISRCTN63657086Phase 2Completed
- Sponsor
- Geigy Foundation
- Start
- May 2015
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of moxidectin, Arterolane and praziquantel in schistosomiasis, sponsored by Geigy Foundation. Primary endpoints: Cure rate for Schistosoma mansoni and Schistosoma haematobium and Egg reduction rate for Schistosoma mansoni and Schistosoma haematobium. Started May 2015; status: completed.
02
Drugs
moxidectinArterolanepraziquantel
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on ISRCTN63657086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63657086.